<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">101127833</journal-id>
<journal-id journal-id-type="pubmed-jr-id">27020</journal-id>
<journal-id journal-id-type="nlm-ta">Expert Opin Ther Targets</journal-id>
<journal-id journal-id-type="iso-abbrev">Expert Opin. Ther. Targets</journal-id>
<journal-title-group>
<journal-title>Expert opinion on therapeutic targets</journal-title>
</journal-title-group>
<issn pub-type="ppub">1472-8222</issn>
<issn pub-type="epub">1744-7631</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26941128</article-id>
<article-id pub-id-type="pmc">5031543</article-id>
<article-id pub-id-type="doi">10.1517/14728222.2016.1162293</article-id>
<article-id pub-id-type="manuscript">NIHMS811826</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Hepatocyte Growth Factor and Alternative Splice Variants - Expression, Regulation and Implications in Osteogenesis and Bone Health and Repair</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Frisch</surname>
<given-names>Rachel N.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="author-notes" rid="FN2">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Curtis</surname>
<given-names>Kevin M.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="author-notes" rid="FN1">§</xref>
<xref ref-type="author-notes" rid="FN2">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Aenlle</surname>
<given-names>Kristina K.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Howard</surname>
<given-names>Guy A.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="author-notes" rid="FN1">§</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Geriatric Research, Education, and Clinical Center, and Research Service, Bruce W. Carter Veterans Affairs Medical Center, Miami, FL 33125, USA</aff>
<aff id="A2"><label>2</label>Biochemistry &amp; Molecular Biology, University of Miami Miller School of Medicine, P.O. Box 016960 Miami, Florida 33101</aff>
<aff id="A3"><label>3</label>Medicine, University of Miami Miller School of Medicine, P.O. Box 016960 Miami, Florida 33101</aff>
<author-notes>
<corresp id="FN1"><label>§</label>Corresponding authors: Kevin M. Curtis, Ph.D., KMC: <email>kevinmcurtis@gmail.com</email>. Guy A. Howard, Ph.D., GAH: <email>ghoward1@med.miami.edu</email></corresp>
<fn fn-type="equal" id="FN2">
<label>*</label>
<p>These authors contributed equally to this article.</p>
</fn>
<fn fn-type="COI-statement" id="FN3">
<p>
<bold>Declaration of Interest</bold>
</p>
<p>The authors were supported by National Institute of Health/National Institute of Arthritis and Musculoskeletal Diseases (GRANT # 5F32AR062990-04), Miami VA Medical Center, University of Miami School of Medicine. KM Curtis is a postdoctoral fellow funded in part by NIH/NIAMS F32 Postdoctoral Grant #5F32AR062990-04. GA Howard is funded in part through veterans affairs career scientist award and veterans affairs merit review grant. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>23</day>
<month>8</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>21</day>
<month>3</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<month>9</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>9</month>
<year>2017</year>
</pub-date>
<volume>20</volume>
<issue>9</issue>
<fpage>1087</fpage>
<lpage>1098</lpage>
<!--elocation-id from pubmed: 10.1517/14728222.2016.1162293-->
<abstract>
<sec id="S1">
<title>Introduction</title>
<p id="P1">Bone marrow-derived mesenchymal stem cells (MSCs) can differentiate into multiple cell types, including osteoblasts, chondrocytes, and adipocytes. These pluripotent cells secrete hepatocyte growth factor (HGF), which regulates cell growth, survival, motility, migration, mitogenesis and is important for tissue development/regeneration. HGF has four splice variants, NK1, NK2, NK3, and NK4 which have varying functions and affinities for the HGF receptor, cMET. HGF promotes osteoblastic differentiation of MSCs into bone forming cells, playing a role in bone development, health and repair.</p>
</sec>
<sec id="S2">
<title>Areas Covered</title>
<p id="P2">This review will focus on the effects of HGF in osteogenesis, bone repair and bone health, including structural and functional insights into the role of HGF in the body.</p>
</sec>
<sec id="S3">
<title>Expert Opinion</title>
<p id="P3">Approximately 6.2 million Americans experience a fracture annually, with 5–10% being mal- or non-union fractures. HGF is important in priming MSCs for osteogenic differentiation <italic>in vitro</italic> and is currently being studied to assess its role during bone repair <italic>in vivo</italic>. Due to the high turnover rate of systemic HGF, non-classic modes of HGF-treatment, including naked-plasmid HGF delivery and the use of HGF splice variants (NK1 &amp; NK2) are being studied to find safe and efficacious treatments for bone disorders, such as mal- or non-union fractures.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Hepatocyte Growth Factor</kwd>
<kwd>HGF</kwd>
<kwd>Bone</kwd>
<kwd>Osteoblastic Differentiation</kwd>
<kwd>Osteoblasts</kwd>
<kwd>Osteoclasts</kwd>
<kwd>cMET</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>